HC Wainwright Has Positive View of Precigen FY2024 Earnings
Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...
HC Wainwright Forecasts Exodus Movement FY2024 Earnings
Analysts at HC Wainwright issued their FY2024 EPS estimates for Exodus Movement in a report issued on Thursday, January 23rd. HC Wainwright analyst K. Dede forecasts that the company will post ...
H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating
H.C. Wainwright analysts have reduced the price target for ALX Oncology (NASDAQ:ALXO) shares to $5 from the previous $25 ...
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright
H.C. Wainwright adjusted its price target for Lexaria Bioscience (NASDAQ:LEXX) to $7.00, down from the previous target of $10.00, while maintaining a Buy rating on the company's shares. With the stock ...
LSI Industries price target raised to $30 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on LSI Industries (LYTS) to $30 from $20 and keeps a Buy rating on the shares. The firm cites ...
Lexaria Bioscience price target lowered to $7 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...
Nasdaq18d
H.C. Wainwright cuts Jasper target, says 50% selloff overdone
H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...
Seeking Alpha24d
Corvus wins new buy from H.C. Wainwright despite recent selloff
H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...
Nasdaq27d
MetaVia initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...
Yahoo Finance3d
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright
https://www.tipranks.com/news/the-fly/arrivent-biopharma-price-target-raised-to-39-from-36-at-h-c-wainwright H.C. Wainwright raised the firm’s price target on ...
cryptopolitan5d
BTCS Inc. to Participate in Fireside Chat with Blockdaemon hosted by H.C. Wainwright
BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a leader in blockchain infrastructure and technology, has announced its ...
Yahoo Finance1mon
Palvella Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $38 price target Palvella’s lead product, QTORIN 3.9% rapamycin anhydrous gel, is currently in ...